Pathology Diagnostics Ltd. based in Cambridge, UK is an award-winning GCLP accredited histopathology contract research organisation providing tissue laboratory and diagnostic services to international pharmaceutical, biotechnology and companion diagnostics clients.
We benefit our clients by providing high quality tissue biomarker data for efficacy studies to progress their pipeline candidates and support their out-licensing needs. We have a proven track record in early discovery & preclinical studies, clinical trials, biomarker and companion diagnostic R&D enabling our clients to make objective data driven decisions on their studies.
Our clients benefit from our full range of services from tissue sourcing to digital pathology & quantitative biomarker analysis. We have validated several hundred biomarker assays are leading experts in immune cell analysis for clients with immunotherapy pipelines; as well as experts in digital pathology & image analysis. Our clients also benefit from assurance of the accuracy, consistency and reliability of our data due to our industry quality accreditations.
PDL has a proven track record in all stages of R&D and has also delivered high value studies as partners/lead coordinators in UK national and international grant-funded programmes for product development of biomarkers and companion diagnostics.
We have strong research credentials as an SME in EU grant funded programmes as follows:
- Partner and coordinator in UK national and EU funded programmes (FP7)
- Registered with EU as an SME for current EU funded programmes
- Over 70% of our scientists have higher research degrees
- Successful delivery of biomarker project in preclinical and clinical samples plus training of visiting scientists in consortia
- Multiple publications in peer-reviewed scientific journals; including Clinical Cancer Research, Science and Nature Medicine
At Pathology Diagnostics Ltd we realise that our clients’ satisfaction is paramount. A selection of real feedback from our clients:
We intend to submit the data from our research study... we think the results are spectacular, with significant findings indicating that quantitative IHC assessment is an accurate scientific tool in the hands of Pathology Diagnostics!
If you would like further information, please contact us.
February 2015: Highlights of the 10th Annual Biomarkers Congress, Manchester, UK: latest pharma industry news
NATURE Publication: Breakthrough Development in Cancer Diagnostics: new in vivo biomarker linked fluorescent probes for fluorescent colonoscopy
Pathology Diagnostics Ltd. presents at Cambridge business seminar on Managing Change
Dublin Pathology 2015 Dublin Ireland
Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met July 2015 Nature Medicine (2015) doi:10.1038/nm.3641